ECO-LEAK Technique: Early Detection of Colorectal Anastomotic Leakage by Transvaginal Ultrasound

NCT05942209 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 766

Last updated 2023-07-21

No results posted yet for this study

Summary

The main hypothesis is that anastomotic leakage can be predicted peri- and postoperatively.To this end, the aim is to establish the accuracy of transvaginal ultrasound with transrectal enema (Ecoenema-TV) for the diagnosis of anastomotic leakage in patients undergoing colorectal anastomosis.

diagnosis of anastomotic leakage in patients undergoing colorectal anastomosis.

Conditions

  • Gynecologic Cancer
  • Anastomotic Leak
  • Cytoreductive Surgery

Interventions

DIAGNOSTIC_TEST

ECO-LEAK transvaginal ultrasound

After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day an ultrasound - ecoenema is performed. First, the Foley catheter is inserted via the transanal route with instillation of 180cc of serum under ultrasound guidance with a probe in the vagina, using a sagittal and midline cut. In case there is the appearance of free pelvic fluid (previously absent) or an increase in free fluid compared to the baseline examination (fluid present at the beginning of the examination) around the anastomosis/pelvic area, the test will be considered positive.

DIAGNOSTIC_TEST

ECO-LEAK with CT-Scan or rectoscopy

After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed, along with an ecoenema.

DIAGNOSTIC_TEST

CT-Scan or rectoscopy

After performing the colorectal anastomosis, the patient is monitored postoperatively both clinically and analytically, with serial laboratory tests including PCR and procalcitonin. In the absence of symptoms on the 4th to 5th day, a CT scan or rectoscopy is performed

Sponsors & Collaborators

  • Clinica Universidad de Navarra, Universidad de Navarra

    collaborator OTHER
  • Instituto de Investigación Hospital Universitario La Paz

    collaborator OTHER
  • Hospital Universitario Virgen de la Arrixaca

    collaborator OTHER
  • Hospital Universitario 12 de Octubre

    collaborator OTHER
  • Imperial College London

    collaborator OTHER
  • Kliniken Essen-Mitte

    collaborator OTHER
  • Charite University, Berlin, Germany

    collaborator OTHER
  • Instituto Nacional de Cancerologia, Columbia

    collaborator OTHER_GOV
  • Hospital Britanico

    collaborator OTHER
  • University of the Republic, Uruguay

    collaborator OTHER
  • Hospital Erasto Gaertner

    collaborator OTHER
  • Instituto de Investigacion Sanitaria La Fe

    lead OTHER

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-17
Primary Completion
2024-11-30
Completion
2025-04-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05942209 on ClinicalTrials.gov